Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weight

Novo Nordisk's weight-loss drug patents have expired in India. Several generic companies have launched their versions, increasing competition. This move is expected to make these treatments more accessible. India's obesity drug market is projected...

With the patent expiry of Novo Nordisk’s weight-loss drugs in India on March 20, at least six generic drugmakers have already launched their versions, intensifying competition in the country’s obesity treatment market.

Also Read: A blockbuster unleashed: What happens when a big fat business explodes?

Lilly’s Mounjaro quickly gained traction in India, last year. A 2.5 mg Mounjaro KwikPen costs about Rs 13,125 for a month’s usage, with the highest 15 mg dose going up to RS 25,781.


Novo cut the price of Wegovy in India by up to 37% in November, pricing its lowest dose of 0.25 mg at Rs 10,850 for a one-month pack. It also launched Ozempic soon after for Rs 8,800 per month for the 0.25 mg dose.

India’s obesity drug market could grow to Rs 8,000 crore by 2030 from about Rs 1,500 crore today, according to Pharmarack estimates.

More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, Reuters reported earlier this week, adding that experts caution this could also lead to misuse and confusion among prescribers as costs fall sharply, Reuters reported earlier this week.
ADVERTISEMENT

Also Read: Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss market

India, the world’s most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet and the International Diabetes Federation.

Here is a look at the weightloss drugs prices in India:



DrugmakerDosage TypeWeekly Price (₹)Monthly Price (₹)Notes on Novo/Lilly Sales in India
Natco PharmaInjection-1,290Generic launch post-patent expiry
Alkem LabsInjection4501,800-
Sun PharmaInjection750–900--
Dr. Reddy’sInjection-4,200-
Lupin / ZydusInjection-2,200-
Torrent PharmaceuticalsOral & Injection-3,999-
Lilly Mounjaro Injection-13,125–25,781Original brand prices
Novo Wegovy Injection-10,850Price cut in Nov; Ozempic Rs 8,800 monthly
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weight
Text Size:AAA
Success
This article has been saved

*

+